cryptocurrency transaction fees list 2021 Top Knowledge

The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.Because yesterday, when the mood was the highest, it was inevitable that the turnover would be enlarged. Today, everyone has calmed down, and the volume will drop. Everyone's willingness to trade is not so strong. Some major institutions have done more by themselves. Typically, they don't want everyone to make money.Although many people are still pessimistic, I am confident that the trend is bullish. Ups and downs will make many people lose money. Everyone will never make money outside their own cognition. It is better to wait patiently in the direction of their own cognition.

3. Generally speaking, today's shrinking and counter-pumping is basically formed, so it is ok to hold shares in the directions mentioned above.For retail investors, today is still more suitable for holding shares to rise. If you bought yesterday, you don't have to worry about it in the short term. As long as you follow the above-mentioned directions of technology, consumption and real estate, at least the policy is supportive, and it is not chasing high in the short term.Judging from the rise in these directions, I think it is very simple for investors now. Just do the following:

Now it is the hope of the above that the stock market will rise, and that technology and consumption will rise. This is not difficult to understand. What is difficult is whether you have the patience and confidence to hold these.3. Generally speaking, today's shrinking and counter-pumping is basically formed, so it is ok to hold shares in the directions mentioned above.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.